Partners-Care New England merger likely to raise premiums

A study from the Rhode Island Office of the Health Insurance Commissioner said the state’s residents would see increases in insurance premiums if Boston-based Partners Healthcare acquires Care New England, thanks to Partners likely using its regional market clout to gain better prices from insurers. 

The proposed acquisition has reached the point where the systems have agreed to enter into a definitive merger agreement—and possibly include Lifespan, Rhode Island’s largest health system. According to health insurers interviewed by the commissioner’s office, Partners would then ask for higher rates.

“Our experience with Partners tells us they like to solve problems with revenue solutions,” said one insurance executive in the report, according to GoLocalProv. “They will say, ‘Hit this price point or we are out of your network—including the whole Massachusetts network.’”

The insurance execs also implied Partners has “been on good behavior” on asking for rate increases in recent years in order to avoid closer scrutiny in Massachusetts and wouldn’t act the same way in a new market where prices are lower. In one example, an interviewee said Partners physician organizations in Massachusetts are up to 50 percent more expensive than the fee schedule for a typical Rhode Island practice.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.